New Drugs Approved in 2020

被引：3

作者：

Ebied, Alex M. ^{[1
]}

Elmariah, Hesham ^{[2
]}

Cooper-DeHoff, Rhonda M. ^{[3
]}

机构：

[1] High Point Univ, Fred Wilson Sch Pharm, Dept Clin Sci, High Point, NC USA

[2] Ross Univ, Sch Med, Bridgetown, Barbados

[3] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA

来源：

AMERICAN JOURNAL OF MEDICINE | 2021年 / 134卷 / 09期

关键词：

Accelerated approval; Fast track; Novel drugs; Priority review; US Food and Drug Administration;

D O I：

10.1016/j.amjmed.2021.03.034

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In 2020, the US Food and Drug Administration approved 53 novel drugs. Thirty-six of the 53 (68%) drugs were reviewed and approved through an expedited review pathway, and 31 of the 53 (58%) were approved for treatment of a rare disease. This review includes a summary of the novel drugs approved by the US Food and Drug Administration in 2020. (C) 2021 Elsevier Inc. All rights reserved.

引用

页码：1096 / 1100

页数：5

共 4 条

[1] [Anonymous], Novel Drug Approvals
[2] Contribution of NIH funding to new drug approvals 2010-2016
Cleary, Ekaterina Galkina
Beierlein, Jennifer M.
Khanuja, Navleen Surjit
McNamee, Laura M.
Ledley, Fred D.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (10) : 2329 - 2334
[3] Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018
DeMartino, Patrick C.
Miljkovic, Milos D.
Prasad, Vinay
[J]. JAMA INTERNAL MEDICINE, 2021, 181 (02) : 162 - 167
[4] US Food and Drug Administration (FDA), ADV HLTH INN NEW DRU

← 1 →